Loading...
XTAI
4737
Market cap126mUSD
Dec 05, Last price  
58.90TWD
1D
0.68%
1Q
-17.33%
Jan 2017
5.37%
IPO
-41.69%
Name

Bionime Corp

Chart & Performance

D1W1MN
XTAI:4737 chart
P/E
—
P/S
2.05
EPS
—
Div Yield, %
3.40%
Shrs. gr., 5y
0.73%
Rev. gr., 5y
-2.31%
Revenues
1.93b
+10.15%
937,752,0001,211,743,0001,476,543,0001,435,022,0001,560,897,0001,524,669,0001,609,718,0001,740,309,0001,820,267,0002,007,222,0002,172,923,0001,668,586,0001,849,924,0002,210,589,0001,755,567,0001,933,746,000
Net income
-127m
L
135,237,000136,050,000179,111,00034,147,00089,929,00054,309,00098,793,000178,790,000149,608,000128,032,000106,258,00062,434,00087,413,00091,025,0006,209,000-127,216,000
CFO
20m
-90.40%
207,558,00013,661,000216,930,00023,575,000128,981,000359,843,000200,365,000457,836,00029,599,000121,898,000405,556,000217,556,000269,722,000142,292,000203,443,00019,530,000
Dividend
Jul 29, 20241.99997 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.
URL
https://www.bionime.com/
IPO date
Aug 26, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT